DDD Group Limited

Belkins
DDD Limited comprises a group of companies which between them offer a complete service to take a health and beauty product from idea to a consumer’s shopping basket. At DDD, we have been making and selling health and beauty products for almost 100 years, and all the skills we have gained in that time are available to you. Our operating companies are run as separate business units, but can all work together to deliver a range of services to our partners. All of our businesses operate with our core purpose at the forefront of how we work: Helping people be at their best in a way we can be proud of.

Related News

BUSINESS INSIGHTS

VIFOR PHARMA DRIVES TRANSFORMATION WITH DIVESTMENT OF NON-CORE FINISHED DRUG MANUFACTURING TO CORDENPHARMA

Vifor Pharma Group | December 17, 2021

news image

Vifor Pharma Group announced the divestment of its finished drug product manufacturing business to CordenPharma, a full-service Contract Development & Manufacturing Organization of APIs, Excipients, Drug Products, and associated Packaging services. This decision reinforces Vifor Pharma’s strategy to transform the company into a multi-brand commercial organization, focusing on its core capabilities in-licensing, partnering and commercializing products in nephrology, and to further grow ...

Read More

US CLINICAL TRIALS OF HYDROXYCHLOROQUINE HIT WARP SPEED COULD SHOW IN WEEKS

CNBC | April 15, 2020

news image

Researchers are working as quickly as science will allow to determine whether hydroxychloroquine, a decades-old malaria drug touted by President Donald Trump as a potential “game changer” in curtailing the Covid-19 pandemic, is effective in fighting the coronavirus. Federal health regulators have fast-tracked approvals for coronavirus research, allowing scientists across the nation to skip through months of red tape on potential treatments and vaccines for the deadly virus. On March ...

Read More

BUSINESS INSIGHTS

ACURX PHARMACEUTICALS TO JOIN THE RUSSELL MICROCAP INDEX®

Acurx Pharmaceuticals, Inc. | September 06, 2021

news image

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company is set to join the Russell Microcap® Index when the market opens on September 20, 2021, according to a preliminary list of additions posted on September 1, 2021. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate gr...

Read More

SMALL TACTICS TO COUNTER BIG PHARMA’S INFLUENCE ON MEDICATION OVERLOAD

STAT | January 28, 2020

news image

Money talks in Washington, D.C., and no sector of the economy speaks more loudly than the pharmaceutical and biotech industry. Its flow of cash has fostered an epidemic of medication overload. Over the past five years, pharma has spent about $1.2 billion lobbying federal lawmakers, far more than any other industry. The industry has massive influence over public policy, much of it devoted in recent months to hindering legislative efforts to lower drug prices. In addition to keeping prices high, t...

Read More
news image

BUSINESS INSIGHTS

VIFOR PHARMA DRIVES TRANSFORMATION WITH DIVESTMENT OF NON-CORE FINISHED DRUG MANUFACTURING TO CORDENPHARMA

Vifor Pharma Group | December 17, 2021

Vifor Pharma Group announced the divestment of its finished drug product manufacturing business to CordenPharma, a full-service Contract Development & Manufacturing Organization of APIs, Excipients, Drug Products, and associated Packaging services. This decision reinforces Vifor Pharma’s strategy to transform the company into a multi-brand commercial organization, focusing on its core capabilities in-licensing, partnering and commercializing products in nephrology, and to further grow ...

Read More
news image

US CLINICAL TRIALS OF HYDROXYCHLOROQUINE HIT WARP SPEED COULD SHOW IN WEEKS

CNBC | April 15, 2020

Researchers are working as quickly as science will allow to determine whether hydroxychloroquine, a decades-old malaria drug touted by President Donald Trump as a potential “game changer” in curtailing the Covid-19 pandemic, is effective in fighting the coronavirus. Federal health regulators have fast-tracked approvals for coronavirus research, allowing scientists across the nation to skip through months of red tape on potential treatments and vaccines for the deadly virus. On March ...

Read More
news image

BUSINESS INSIGHTS

ACURX PHARMACEUTICALS TO JOIN THE RUSSELL MICROCAP INDEX®

Acurx Pharmaceuticals, Inc. | September 06, 2021

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company is set to join the Russell Microcap® Index when the market opens on September 20, 2021, according to a preliminary list of additions posted on September 1, 2021. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate gr...

Read More
news image

SMALL TACTICS TO COUNTER BIG PHARMA’S INFLUENCE ON MEDICATION OVERLOAD

STAT | January 28, 2020

Money talks in Washington, D.C., and no sector of the economy speaks more loudly than the pharmaceutical and biotech industry. Its flow of cash has fostered an epidemic of medication overload. Over the past five years, pharma has spent about $1.2 billion lobbying federal lawmakers, far more than any other industry. The industry has massive influence over public policy, much of it devoted in recent months to hindering legislative efforts to lower drug prices. In addition to keeping prices high, t...

Read More

Resources

resource image

PHARMACY MARKET

A pharma outsourcing mission

Article

resource image

BUSINESS INSIGHTS

2021 global life sciences outlook

infographic

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us